Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
1.
J Cosmet Laser Ther ; 25(5-8): 77-85, 2023 Nov 17.
Article in English | MEDLINE | ID: mdl-38373440

ABSTRACT

Facial and neckline telangiectasias have an underestimated yet important impact on quality of life of patients with systemic scleroderma (SSc). This monocentric, prospective, open-label, intra-patient comparative study was conducted in 21 consecutive patients with SSc. Patients underwent 4 sessions of PDL 8 weeks apart. A final quadruple assessment was performed by several raters 2 months after the last session, based on the following criteria: change in telangiectasia number; subjective improvement score (LINKERT scale); impact on the quality of life (QoL; SKINDEX score); visual analog pain scale; adverse effects (AEs), including treatment discontinuation for PDL-induced purpura and patient satisfaction. The mean telangiectasia number decreased by 5 (32%) at the end of the protocol. Eighteen patients (85.7%) reported an improvement or a strong improvement, versus 73.81% for the expert committee. Immediate session pain (mean = 3.4/10) was slightly less than overall pain (mean = 4.6/10). Ten patients (47%) experienced at least one AE (oozing/crusts, edema, epidermal blistering), including PDL-induced purpura in 3 patients (14%). AEs were mostly transient (<1 week) and mild (CTCAE grade 1). All QoL parameters improved after treatment, and 85% of patients were satisfied.


Subject(s)
Lasers, Dye , Purpura , Scleroderma, Systemic , Telangiectasis , Humans , Lasers, Dye/adverse effects , Pain , Prospective Studies , Quality of Life , Scleroderma, Systemic/complications , Telangiectasis/etiology , Telangiectasis/therapy , Treatment Outcome
3.
Br J Dermatol ; 184(6): 1106-1112, 2021 06.
Article in English | MEDLINE | ID: mdl-33067805

ABSTRACT

BACKGROUND: The Bullous Pemphigoid Disease Area Index (BPDAI) score has been proposed to provide an objective measure of bullous pemphigoid (BP) activity. OBJECTIVES: The objective of this study was to calculate BPDAI cut-off values defining mild, moderate and severe BP. We also aimed to assess the interrater reliability and correlation with the number of daily new blisters, and anti-BP180 and anti-BP230 antibodies. METHODS: Severity scores were recorded by two blinded investigators. Anti-BP180 and anti-BP230 antibodies were measured using an enzyme-linked immunosorbent assay (ELISA). Cut-off values defining mild, moderate and severe subgroups were calculated based on the 25th and 75th percentiles of the BPDAI score. RESULTS: In total, 285 patients with BP were enrolled from 50 dermatology departments in Europe. Median BPDAI activity was 37·5 points (range 0-164). Cut-off values corresponding to the first and third quartiles of the BPDAI score were 20 and 57, respectively; thus, these values were used to define mild (≤ 19), moderate (≥ 20 and ≤ 56) and severe (≥ 57) BP. The median BPDAI score for patients with ≤ 10 daily new blisters was 26 [interquartile range (IQR) 17-45], and for patients with > 10 daily new blisters the median score was 55 (IQR 39-82). The BPDAI intraclass correlation coefficient measured at baseline was 0·97 and remained higher than 0·90 up to month 6. The improvement in the BPDAI score was correlated with the absolute decrease in anti-BP180 ELISA value (Spearman's rank r = 0·34, P < 0·004), but not with anti-BP230 antibodies (r = 0·17, P = 0·15). CONCLUSIONS: This study suggests cut-off values of 20-57 for BPDAI to distinguish mild, moderate and severe BP, and confirms that it is a robust tool to assess BP severity precisely.


Subject(s)
Pemphigoid, Bullous , Autoantibodies , Autoantigens , Dystonin , Enzyme-Linked Immunosorbent Assay , Europe , Humans , Non-Fibrillar Collagens , Pemphigoid, Bullous/diagnosis , Reproducibility of Results , Severity of Illness Index
6.
Ann Dermatol Venereol ; 146(8-9): 550-556, 2019 Sep.
Article in French | MEDLINE | ID: mdl-30929872

ABSTRACT

BACKGROUND: Statin-induced necrotizing autoimmune myopathy (NAM) has been recently characterized. Herein we report an accurate description of the clinical and histological characteristics of cutaneous rash associated with NAM. PATIENTS AND METHODS: A 61-year-old woman presented a skin rash involving the face, the chest and the back of the hands with heliotropic distribution coupled with proximal symmetrical muscle weakness. Rosuvastatin had been introduced 8 months earlier. Creatinine kinase levels were dramatically raised. Screening for lupus and dermatomyositis antibodies were negative. The cutaneous histology was consistent with neutrophilic lupus while a muscle biopsy revealed no inflammation but showed necrotic and regenerative myofibres. Finally, antibodies directed against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) were found at high levels (1658UA/ml vs. normal<13.0UA/ml), resulting in diagnosis of necrotizing autoimmune myopathy (NAM). Intensive immunosuppressive therapy resulted in excellent improvement. DISCUSSION: NAM is a severe acquired autoimmune myopathy characterised by severe proximal weakness and specific positive antibodies (anti-HMGCR or anti-signal recognition particle). It is classically associated with statin use. Some extra-muscular symptoms have been described in previous studies. We report the third accurate description of cutaneous rash associated with statin-induced NAM involving HMGCR antibodies. The skin rash was evocative of connective tissue disease and our diagnosis was based on immunology and muscle histology. CONCLUSION: Dermatologists must be able to recognise this rare entity of "pseudo-dermatomyositis" and then discontinue statin intake if present and carry out further investigations consisting of muscle biopsy and serological tests.


Subject(s)
Autoantibodies/blood , Autoimmune Diseases/blood , Autoimmune Diseases/chemically induced , Hydroxymethylglutaryl CoA Reductases/immunology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Muscle, Skeletal/pathology , Muscular Diseases/blood , Muscular Diseases/chemically induced , Rosuvastatin Calcium/administration & dosage , Autoimmune Diseases/complications , Autoimmune Diseases/diagnosis , Dermatomyositis/etiology , Female , Humans , Middle Aged , Muscular Diseases/complications , Muscular Diseases/diagnosis , Necrosis/blood , Necrosis/chemically induced , Necrosis/complications , Necrosis/diagnosis , Syndrome
7.
Ann Dermatol Venereol ; 142(11): 680-4, 2015 Nov.
Article in French | MEDLINE | ID: mdl-26362130

ABSTRACT

BACKGROUND: Mid-dermal elastolysis (MDE) is a rare acquired disease of elastic tissue histologically characterized by focal loss of elastic fibres within the mid-dermis. While the mechanisms leading to MDE remain unknown, increased degradation of elastic fibres may be involved. Many factors potentially triggering such degradation have been suggested. PATIENTS AND METHODS: A 58-year-old man consulted for an asymptomatic reticulated eruption that began in the area of a pacemaker implanted six weeks earlier. The eruption consisted of erythematous polycyclic and coalescing macules with a wrinkled centre. Histopathology with orcein staining revealed focal loss of elastic fibres in the superficial reticular dermis only. Hypersensitivity reaction to any components of the pacemaker was ruled out by means of allergy exploration. Laboratory investigations including autoimmunological and haematological factors were unremarkable. A diagnosis was made of a reticular variant of MDE following insertion of a pacemaker. DISCUSSION: We report the second case of MDE following the insertion of a pacemaker, which could have triggered an inflammatory response directed specifically towards the elastic fibres.


Subject(s)
Dermis/pathology , Elastic Tissue/pathology , Pacemaker, Artificial/adverse effects , Skin Diseases/etiology , Skin Diseases/pathology , Erythema/etiology , Humans , Male , Middle Aged
8.
Hosp Community Psychiatry ; 33(3): 212-5, 1982 Mar.
Article in English | MEDLINE | ID: mdl-7061057

ABSTRACT

The reliability and validity of psychiatrists' predictions of a patient's potential for suicide are increasingly being questioned, both by mental health professionals and by the courts. The authors describe a study conducted in 1978 to measure the reliability with which a team of mental health professionals assessed suicidal risk in a group of 16 patients seen in videotaped interviews. They found that the highest reliability was on an item that assessed the seriousness of the patient's past suicide attempts; the lowest reliability came in assessing the patient's risk of death from accidents, homicide, or neglect of self. Over-all, the authors say, the clinicians made their judgments based on rational and consistent evaluation of the data.


Subject(s)
Suicide/psychology , Adult , Aged , Bipolar Disorder/psychology , Depressive Disorder/psychology , Humans , Middle Aged , Personality Disorders/psychology , Risk , Schizophrenic Psychology
SELECTION OF CITATIONS
SEARCH DETAIL
...